Articles

Updated analysis of the phase 1 CRB-401 study supports a favorable clinical benefit–risk profile for the BCMA-directed CAR T-cell therapy, idecabtagene vicleucel, in RRMM at target dose levels of ≥150 × 106 CAR+ T-cells. Read More ›

The combination regimen of thalidomide, prednisone, and methotrexate demonstrated greater efficacy than treatment with cyclosporine and prednisone in patients with large granular lymphocytic leukemia and with limited adverse events. Read More ›

Preliminary results from the phase 1b/2 CARTITUDE-1 study reveal early, deep, and durable responses and a safety profile consistent with prior studies with a single low-dose infusion of ciltacabtagene autoleucel in heavily pretreated patients with RRMM. Read More ›

Two-year fixed-duration treatment with venetoclax-rituximab demonstrates durable response, with a substantial proportion of patients retaining undetectable minimal residual disease 36 months after treatment cessation. Read More ›

In the FORTE trial, patients with NDMM who were transplant-eligible experienced significantly improved progression-free survival with carfilzomib + lenalidomide + dexamethasone (KRd) induction-ASCT-KRd consolidation versus either 12 KRd cycles or carfilzomib + cyclophosphamide + dexamethasone (KCd) induction-ASCT-KCd consolidation. Read More ›

The ICARIA-MM investigators studied the effects of isatuximab + pomalidomide and dexamethasone in the subgroup of frail patients with RRMM, and results support use of the regimen among these patients. Read More ›

Interim results from a phase 2 trial exploring the response to ixazomib, lenalidomide, and dexamethasone induction followed by a single autologous stem-cell transplantation, IRd consolidation, and risk-based maintenance showed an overall response rate of 93%. Read More ›

Preliminary results from this phase 1b/2 study of cobimetinib alone or plus venetoclax, with or without atezolizumab, in patients with RRMM show manageable toxicity, moderate efficacy overall, and higher efficacy for t(11;14) patients. Read More ›

Preliminary results from the GO39775 study show promising efficacy and manageable toxicity for BFCR4350A as monotherapy in patients with RRMM with high-risk cytogenetics, triple-class refractory disease, and/or prior exposure to anti-CD38 monoclonal antibodies, CAR T-cells, or antibody–drug conjugates. Read More ›

The interim results from a phase 2 trial examining the response to ixazomib, lenalidomide, and dexamethasone induction in newly diagnosed, transplant-eligible patients showed an overall response rate of 93%. Read More ›